Richard Chen Mao
Direktor/Vorstandsmitglied bei Stimwave Technologies, Inc.
Profil
Richard Chen Mao currently works at Stimwave Technologies, Inc., as Director.
Aktive Positionen von Richard Chen Mao
Unternehmen | Position | Beginn |
---|---|---|
Stimwave Technologies, Inc.
Stimwave Technologies, Inc. BiotechnologyHealth Technology Part of Curonix LLC, Stimwave Technologies, Inc. is a privately held medical device company based in Pompano Beach, FL. Stimwave specializes in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators. These miniature neurostimulators offer patients a convenient, safe, minimally invasive, and cost-effective solution for pain management. The company's goal is to become the leading provider of neuromodulation technology, making it more accessible to patients globally and reducing the economic burden of pain management. Stimwave's FDA-cleared product portfolio includes peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) products that provide a drug-free alternative for treating chronic pain by blocking pain signals to the brain. The CEO of the company is Aure Bruneau. Stimwave operates worldwide through its operating subsidiaries and was acquired by Curonix LLC on November 01, 2022. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Stimwave Technologies, Inc.
Stimwave Technologies, Inc. BiotechnologyHealth Technology Part of Curonix LLC, Stimwave Technologies, Inc. is a privately held medical device company based in Pompano Beach, FL. Stimwave specializes in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators. These miniature neurostimulators offer patients a convenient, safe, minimally invasive, and cost-effective solution for pain management. The company's goal is to become the leading provider of neuromodulation technology, making it more accessible to patients globally and reducing the economic burden of pain management. Stimwave's FDA-cleared product portfolio includes peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) products that provide a drug-free alternative for treating chronic pain by blocking pain signals to the brain. The CEO of the company is Aure Bruneau. Stimwave operates worldwide through its operating subsidiaries and was acquired by Curonix LLC on November 01, 2022. | Health Technology |